PBAC's latest decision on Leflunomide: Recommended with restriction (2007). Considered for Initial treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.
PBAC outcome
Recommended with restriction
Authority required
ICER (AUD/QALY)
$15k/QALY
Base-case
Submissions
1
first 2007
Submissions
1
2007 → 2007
Eligible population
Severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate
Therapy area
Rheumatology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Key trials
TOPAS, TOPAS (Mease et al, 2000), TOPAS (Mease et al, 2004)